Long-term implications of further ST elevation during thrombolytic therapy on left ventricular function. 2013

Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain. 5751jfb@gmail.com

BACKGROUND Long-term effects on the left ventricular (LV) function of acute ST re-elevation (STRE) during thrombolysis in ST segment elevation myocardial infarction (STEMI) patients have not been investigated. METHODS Patients with anterior STEMI treated with TNK within 12 h from symptom onset (n=191) were investigated. We compared the clinical, the electrocardiographic, and the angiographic data of patients with STRE (additional ≥2.0 mm ST elevation during the first 60 min, followed by >50% ST resolution, n=31) with those with conventional ST resolution (>50%, n=88) and those without ST resolution (<50%, n=72). We also compared the ejection fraction (EF) and LV volumes by echocardiography in the acute phase and at 12 months between the three groups. RESULTS Maximum ST elevation before TNK was higher in conventional ST resolution patients than in the other two groups (P=0.01) and additional STRE was 4.7±2.4 mm. Time from pain onset to TNK in STRE and ST resolution groups was similar but shorter than that in patients without ST resolution (P=0.01), whereas the levels of creatine kinase MB mass, EF, and LV volumes were comparable in the three groups. At 12 months, EF was also similar in patients with STRE than in those with ST resolution (51±8 vs. 53±12%, P=0.52), but LV systolic (60±24 vs. 53±12 ml, P=0.01) and diastolic volumes (124±39 vs. 101±31 ml, P=0.02) were significantly larger in the former. CONCLUSIONS STRE during lytic therapy is associated with greater ventricular dilatation at 12 months than conventional ST resolution, suggesting an impaired reperfusion process. These differences, however, are often not visible in the acute phase.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013318 Stroke Volume The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume. Ventricular Ejection Fraction,Ventricular End-Diastolic Volume,Ventricular End-Systolic Volume,Ejection Fraction, Ventricular,Ejection Fractions, Ventricular,End-Diastolic Volume, Ventricular,End-Diastolic Volumes, Ventricular,End-Systolic Volume, Ventricular,End-Systolic Volumes, Ventricular,Fraction, Ventricular Ejection,Fractions, Ventricular Ejection,Stroke Volumes,Ventricular Ejection Fractions,Ventricular End Diastolic Volume,Ventricular End Systolic Volume,Ventricular End-Diastolic Volumes,Ventricular End-Systolic Volumes,Volume, Stroke,Volume, Ventricular End-Diastolic,Volume, Ventricular End-Systolic,Volumes, Stroke,Volumes, Ventricular End-Diastolic,Volumes, Ventricular End-Systolic

Related Publications

Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
July 1993, American heart journal,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
January 1994, The Journal of the Association of Physicians of India,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
January 2015, Clinical and experimental hypertension (New York, N.Y. : 1993),
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
April 2021, Revista portuguesa de cardiologia,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
June 1991, The American journal of cardiology,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
February 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
January 1995, Clinical science (London, England : 1979),
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
March 2024, Irish medical journal,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
April 2021, Critical care medicine,
Jaume Figueras, and Ivo Roca, and José A Barrabés, and Rosa-Maria Lidón, and David Garcia-Dorado
November 2018, The American journal of cardiology,
Copied contents to your clipboard!